Pharmacological properties
Interferon alpha-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulatory effect. the complex composition of laferobion causes a number of new effects: in combination with tocopherol acetate and ascorbic acid, the antiviral activity of recombinant interferon alpha-2b increases 10–14 times, its immunomodulatory effect on T- and B-lymphocytes is enhanced, the content of immunoglobulin is normalized, e. antibodies are not formed , neutralizing the antiviral activity of recombinant interferon alpha-2b, even when using interferon for 2 years, the functioning of the endogenous system is normalized.
pharmachologic effect
The active ingredient Laferobion has antiviral, antitumor and immunomodulatory effects, while it is recombinant human interferon and has no toxic effects.
Laferobion reaches its maximum concentration when administered subcutaneously or intramuscularly after 4-10 hours.
Laferobion increases immunomodulatory activity, suppresses the proliferation and growth of viruses in infected cells. According to reviews, Laferobion is effective and safe in the treatment of infants from various infectious diseases.
Application
For children: in complex therapy of ARVI, the recommended doses are:
For newborns and premature babies, the drug is prescribed 150,000 IU, 2 suppositories per day with a 12-hour interval. Courses of treatment and breaks between courses are 5 days.
For premature newborns with a gestational age of less than 34 weeks, prescribe the drug 150,000 IU 3 times a day (every 8 hours) rectally. The course is 5 days.
Children aged 1 to 7 years - 500,000 IU 2 times a day.
Children aged 7–14 years - 1,000,000 IU 2 times a day for 5 days.
Use of the drug Laferobion
Lyophilisate for nasal solution For treatment purposes, Laferobion is used at an early stage of the disease when the first clinical symptoms appear. The earlier it was used, the higher the effectiveness of the drug. In the treatment of influenza and other acute respiratory viral infections and viral-bacterial infections, the drug is used by spraying, instillation or inhalation. When sprayed or instilled, a drug with an activity of 50,000–100,000 IU is administered 0.25 ml (5 drops) into each nasal passage after 1–2 hours, but not less than 6 times a day for 2–3 days. The most effective is inhalation. Ultrasonic inhalers are recommended for this purpose. For one administration, use 3 bottles of the drug, the contents of which are dissolved in 5 ml of water. By inhalation, the drug is administered through the mouth and nose 2 times a day. When treating newborns, a solution of the drug Laferobion with an activity of 50,000 IU is instilled in 2-3 drops into each nasal passage 4-6 times a day for 3-5 days. It is recommended to alternately introduce turundas moistened with a solution of the drug into the nasal passages for 10–15 minutes. For the purpose of prevention, the administration of Laferobion should be started in case of an immediate threat of infection and continued as long as there is a risk of infection. For the prevention of influenza and other acute respiratory viral infections and viral-bacterial infections, the drug Laferobion is used by spraying or instilling its aqueous solution with an activity of 50,000–100,000 IU per 1 ml. To obtain an aqueous solution, open the bottle with the drug immediately before use and add sterile distilled or boiled water, cooled to room temperature. To obtain a solution of a drug with an activity of 50,000 IU in 1 ml, add 2 ml of water to the bottle, and with an activity of 100,000 IU in 1 ml - 1 ml of water. Then the bottle is gently shaken until its contents are completely dissolved. Spraying of the drug can be carried out using sprayers of any system. 0.25 ml of the solution must be administered into each nasal passage 2 times a day with an interval of at least 6 hours. When instilled, the drug is administered 5 drops into each nasal passage 2 times a day with an interval of at least 6 hours. Lyophilisate for p -ra for injection is used intramuscularly or subcutaneously, dissolving the contents of the ampoule or bottle in 1 ml of water for injection immediately before use. Viral diseases. For acute hepatitis B (mild, moderate and severe forms), Laferobion is administered at a dose of 1 million IU 2 times a day for 5–6 days, then the dose is reduced to 1 million IU per day and administered for another 5 days. If necessary (after control biochemical blood tests to assess the functional state of the liver), treatment can be continued for another 2 weeks, during which the drug is administered at a dose of 1 million IU 2 times a week. Laferobion is most effective at the beginning of the icteric period up to 5 days of jaundice; in the long term, the administration of the drug is less effective. Laferobion is ineffective in the initial period of hepatic coma and in the cholestatic variant of the disease. For chronic active hepatitis B, Laferobion is prescribed at a dose of 3 million–6 million IU 3 times a week for 24 weeks. If after administration of the drug for 12 weeks there is no clinical, biochemical improvement and/or disappearance of HbeAg, treatment with Laferobion is discontinued. For chronic hepatitis C, Laferobion is prescribed at a dose of 3 million IU 3 times a week for 24 weeks. If after administration of the drug for 4 weeks a 50% decrease in ALT activity in the blood plasma is not detected, the dose of the drug is increased to 6 million IU 3 times a week. Treatment with Laferobion is completed if, after 12 weeks of use of the drug, no clinical and biochemical improvement is noted. For tick-borne encephalitis, Laferobion is effective for meningeal forms of tick-borne encephalitis, the causative agent of which is widespread. Laferobion is administered at a dose of 1 million–3 million IU 2 times a day for 10 days. Then maintenance treatment is prescribed - 5 times 1 million–3 million IU every 2 days. Oncological diseases. The general principle of using interferon in cancer is to prescribe the maximum dose that the patient can tolerate over a sufficiently long period (months, years). Since interferon alpha has a cytostatic effect, maintenance treatment with Laferobion should be continued after achieving an objective effect - hematological remission, regression of the solid tumor focus or stabilization of the disease. For hairy cell leukemia, Laferobion is administered 3 million IU daily. After achieving hematological remission, they switch to maintenance therapy of 3 million IU 3 times a week. For chronic myeloid leukemia, Laferobion is used at a dose of 9 million IU daily. After achieving hematological remission, maintenance therapy is prescribed at a dose of 9 million IU 3 times a week. For renal cell carcinoma, Laferobion is administered at a dose of 18 million IU 3 times a week. The objective effect (complete or partial regression of metastases) appears after 8–12 weeks of treatment with Laferobion or later. When the therapeutic effect of stabilization of the disease is achieved, maintenance treatment is continued at 18 million IU 3 times a week. For Kaposi's sarcoma on the background of AIDS, Laferobion is administered every day at 36 million IU. The drug is used for a long time, except in cases of rapid progression of the disease or severe intolerance. After the effect appears, maintenance therapy is prescribed at 18 million IU 3 times a week. For cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome), Laferobion is prescribed at a dose of 18 million IU daily. For malignant melanoma, Laferobion is administered 18 million IU daily. After achieving an objective effect (complete or partial regression of metastases), maintenance therapy is prescribed at a dose of 18 million IU 3 times a week. To prolong remission and increase the life expectancy of patients after surgical removal of the primary tumor of stage I–II melanoma or regional lymph nodes with metastases, auxiliary treatment with Laferobion is used at a dose of 18,000,000 IU 3 times a week.
Contraindications
Hypersensitivity to the components of the drug; the patient has thyroid dysfunction; the presence of severe visceral disorders in patients with Kaposi's sarcoma; severe cardiovascular diseases; psoriasis; severe dysfunction of the liver and/or kidneys; epilepsy and other diseases of the central nervous system (including functional ones); chronic hepatitis against the background of progressive or decompensated cirrhosis of the liver; chronic hepatitis in patients receiving or recently receiving immunosuppressant therapy (except for a short course of corticosteroid therapy); history of autoimmune hepatitis or other autoimmune diseases. inhibition of the myeloid lineage of hematopoiesis.
Indications for use of the drug Laferobion
Laferobion is used in complex therapy of adults and children for:
- acute and chronic viral hepatitis B (moderate and severe forms);
- acute viral, bacterial and mixed infections, including in newborns;
- acute and chronic septic diseases of viral and bacterial nature, including disseminated forms of acute and chronic sepsis;
- herpetic infections of various localizations: herpes zoster, multiple skin herpetic rashes; genital herpetic infection; herpetic keratoconjunctivitis and keratouveitis, etc.;
- laryngeal papillomatosis;
- multiple sclerosis;
- malignant tumors;
- melanoma of the skin and eyes;
- cancer of the kidney, bladder, ovary, breast;
- Kaposi's sarcoma;
- multiple myeloma.
Side effects
All adverse reactions associated with the use of laferobion, minor or moderate, usually disappear after treatment.
General disorders: when Laferobion is administered, flu-like symptoms are possible: chills, increased body temperature, fatigue, lethargy, as well as headache, muscle pain, joint pain, increased sweating; rarely - vomiting, dizziness, hot flashes. Hypersensitivity reactions to the drug may occur.
Disorders of the hematopoietic system: with prolonged use, leukopenia, thrombocytopenia, anemia, and nosebleeds are possible.
Gastrointestinal and liver disorders: increased levels of ALT and AST, alkaline phosphatase, loss of appetite, impaired liver function.
Endocrine disorders: thyroid dysfunction.
Disorders of the central and peripheral nervous system: with prolonged use, dizziness, sleep disturbance, confusion, anxiety and depression, increased excitability, drowsiness, ataxia, and paresthesia are possible.
Cardiovascular system disorders: possible hypertension or hypotension; rarely - tachycardia.
Disorders of the skin and subcutaneous tissues: allergic reactions, including rash (including herpetic), itching, hyperemia.
Respiratory system disorders: cough.
Other: changes at the injection site, visual impairment, renal dysfunction, electrolyte imbalance.
special instructions
Treatment with laferobion should be carried out under medical supervision.
With long-term use of the drug, a general blood count, liver, kidney and thyroid function are monitored.
All patients, before starting and regularly during treatment, are recommended to undergo a detailed analysis of peripheral blood, with mandatory qualitative and quantitative examination of blood parameters, as well as a biochemical blood test, including determination of electrolytes, calcium, liver enzymes and creatinine.
In all patients receiving the drug, it is recommended to carefully monitor plasma albumin levels and prothrombin time.
Prescribe the drug with caution if you have a history of diseases such as diabetes mellitus with episodes of ketoacidosis and COPD, bleeding disorders (including pulmonary thrombophlebitis), and severe myelosuppression.
When treating with the drug, it is necessary to ensure adequate hydration of the body; If fever occurs, other causes of its occurrence should be excluded. It is recommended to use the drug against the background of antihistamine and antipyretic therapy.
The development of severe and moderate side effects requires dose adjustment, and in some cases, discontinuation of treatment.
Stop using the drug in the following cases: prolongation of blood clotting time (in patients with chronic hepatitis), manifestations of pulmonary syndrome and X-ray detection of infiltrate or impaired pulmonary function, appearance or increase in the severity of visual impairment, impaired thyroid function (abnormal TSH level), decreased plasma albumin levels and a decrease in prothrombin time.
If an immediate hypersensitivity reaction develops (urticaria, angioedema, bronchospasm, anaphylaxis), the drug should be immediately discontinued and appropriate measures taken.
After the expiration date, the use of the drug is unacceptable. The drug is not subject to repeated quality control and extension of the shelf life after its expiration.
Use during pregnancy and lactation. There are no data on the use of the drug during pregnancy and lactation.
Children. Used in pediatric practice (see APPLICATION).
The ability to influence reaction speed when driving vehicles or working with other mechanisms. Some adverse CNS effects associated with the use of the drug may affect the ability of patients to drive vehicles and operate potentially dangerous machinery.
Mode of application
The drug is administered into each nasal passage.
Before using the drug, you must take a supine or sitting position, tilt your head slightly back and turn towards the nasal passage into which the drops will be instilled. Without touching the inner walls of the nose with the dropper of the bottle, instill the drug. Immediately after instillation, in order to distribute the drug evenly throughout the nasal mucosa, it is recommended to massage the wings of the nose from the outside with your fingers for several minutes.
At the first sign of ARVI (within 5 days)
Adults - 3 drops in each nasal passage 5-6 times a day (single dose - 24,000 IU, daily dose - 120,000 - 144,000 IU).
Children. For newborns and children under 1 year old - 1 drop in each nasal passage 5 times a day (single dose - 8000 IU, daily dose - 40,000 IU).
Children aged 1 to 3 years - 2 drops in each nasal passage 3-4 times a day (single dose - 16,000 IU, daily dose - 48,000 - 64,000 IU).
Children aged 3 to 14 years - 2 drops in each nasal passage 4-5 times a day (single dose - 16,000 IU, daily dose - 64,000 - 80,000 IU).
Children aged 14 to 18 years - 3 drops in each nasal passage 5-6 times a day (single dose - 24,000 IU, daily dose - 120,000 - 144,000 IU).
For the prevention of respiratory viral infections in adults
In case of contact with a patient and in case of hypothermia - 3 drops 2 times a day for 5-7 days. If necessary, preventive courses are repeated. For single contact, a single application is sufficient.
When there is a seasonal increase in incidence - once in the morning with an interval of 1-2 days.
Scheme for using nasal drops in a bottle sealed with a Microdispenser-dropper:
- Remove the protective cap from the bottle.
- Before using the drops for the first time, return the bottle with the nozzle down and make a few test presses on the dispenser pump.
- Place the end of the nozzle alternately in each nasal passage and press the dispenser pump the required number of times in accordance with the dosage.
- After use, close the bottle with the cap.
Interactions
The drug should be used with caution simultaneously with opioid drugs, analgesics, hypnotics and sedatives (potentially causing a myelosuppressive effect).
When used simultaneously with drugs that are metabolized by oxidation (including xanthine derivatives - aminophylline and theophylline), the possibility of Laferobion's influence on oxidative metabolic processes should be taken into account. The concentration of theophylline in blood plasma must be monitored and, if necessary, the dosage regimen must be adjusted.
When using the drug in combination with chemotherapeutic drugs (cytarabine, doxorubicin, teniposide, cyclophosphamide), the risk of developing life-threatening toxic effects (their severity and duration) increases.
When used simultaneously with zidovudine, the risk of developing neutropenia increases.
Features of application
To avoid the spread of infection, individual use of the bottle is recommended.
Avoid contact of the drug with the mucous membrane of the eyes.
Use during pregnancy or breastfeeding
Use is contraindicated.
Children
The drug is used for children from birth at the first signs of ARVI.
The ability to influence the reaction rate when driving vehicles or other mechanisms
Does not affect.
Note!
Description of the drug Laferobion supp. 150 thousand ME No. 10 on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
